Antiproliferative Effect of Vitamin D in Prostate Epithelial Cells

  • Kerry L. Burnstein


In the last decade, vitamin D and vitamin D analogs have emerged as potential chemotherapeutic agents for the treatment of a variety of cancers. The anticancer activity of vitamin D-based regimens is due, in large part, to inhibition of cell growth and promotion of cellular differentiation. Consistent with these cellular actions, compelling population-based and epidemiologic studies support the protective effects of vitamin D against prostate and certain other cancers. Cell cycle regulation is central to vitamin D’s antiproliferative effects. This chapter focuses primarily on the mechanisms of this cell cycle inhibition in prostate cancer cells and, for illustrative purposes, also highlights vitamin D effects on gene expression and cell cycle in cells derived from other solid tumors. Understanding the fundamental principles of vitamin D synthesis, metabolism and action has led to novel vitamin D-based therapeutic strategies, which are illustrated here. Finally, the possible molecular basis for resistance to vitamin D-mediated growth inhibition is considered.


Prostate Cancer Cell LNCaP Cell Anti Proliferative Effect Prostate Cancer Cell Line Human Prostate Cancer Cell 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Barreto AM, Schwartz GG, Woodruff R, Cramer SD. 2000. 25-Hydroxyvitamin D3, the prohormone of 1,25-dihydroxyvitamin D3, inhibits the proliferation of primary prostatic epithelial cells. Cancer Epidemiol Biomarkers Prev.; 9:265–270.PubMedGoogle Scholar
  2. Baserga R. 2000. Insulin-like growth factor I receptor signalling in prostate cancer cells. Growth Horm IGF Res. 10:S43–44.PubMedCrossRefGoogle Scholar
  3. Beer TM, Hough KM, Garzotto M, Lowe BA, Henner WD. 2001. Weekly high-dose calcitriol and docetaxel in advanced prostate cancer. Semin Oncol 28:49–55PubMedCrossRefGoogle Scholar
  4. Berges RR, Vukanovic J, Epstein JI, CarMichel M, Cisek L, Johnson DE, Veltri RW, Walsh PC, Isaacs JT 1995 Implication of cell kinetic changes during the progression of human prostatic cancer. Clin Cancer Res 5:473–80Google Scholar
  5. Bikle DD. 1992. Clinical counterpoint: vitamin D: new actions, new analogs, new therapeutic potential. Endocr Rev. 13:765–784.PubMedGoogle Scholar
  6. Blagosklonny MV., Wu GS, Omura S. and El-Deiry WS. 1996. Proteasome-dependent regulation of p21WAF1/CIP1 expression. Biochem. Biophys. Res. Commun., 227, 564–569.PubMedCrossRefGoogle Scholar
  7. Blutt SE, Allegretto EA, Pike JW, Weigel NL. 1997. 1,25-dihydroxyvitamin D3 and 9-cisretinoic acid act synergistically to inhibit the growth of LNCaP prostate cells and cause accumulation of cells in G1. Endocrinology. 138:1491–1497.PubMedCrossRefGoogle Scholar
  8. Blutt SE, Polek TC, Stewart LV, Kattan MW, Weigel NL. 2000. A calcitriol analogue, EB1089, inhibits the growth of LNCaP tumors in nude mice. Cancer Res. 60:779–782.PubMedGoogle Scholar
  9. Bookstein R, Shew JY, Chen PL, Scully P, Lee WH. 1990. Suppression of tumorigenicity of human prostate carcinoma cells by replacing a mutated RB gene. Science. 247:712–715.PubMedCrossRefGoogle Scholar
  10. Boyle BJ, Zhao XY, Cohen P, Feldman D. 2001. Insulin-like growth factor binding protein-3 mediates 1 alpha,25-dihydroxyvitamin D(3) growth inhibition in the LNCaP prostate cancer cell line through p21/WAF1. J Urol. 165:1319–1324.PubMedCrossRefGoogle Scholar
  11. Campbell MJ, Elstner E, Holden S, Uskokovic M, Koeffler HP. 1997a. Inhibition of proliferation of prostate cancer cells by a 19-nor-hexafluoride vitamin D3 analogue involves the induction of p21waf1, p27kip1 and E-cadherin. J Mol Endocrinol. 19:15–27.PubMedCrossRefGoogle Scholar
  12. Campbell MJ, Gombart AF, Kwok SH, Park S, Koeffler HP. 2000. The anti-proliferative effects of 1alpha,25(OH)2D3 on breast and prostate cancer cells are associated with induction of BRCA1 gene expression. Oncogene. 19:5091–5097.PubMedCrossRefGoogle Scholar
  13. Campbell MJ, Koeffler HP. 1997. Toward therapeutic intervention of cancer by vitamin D compounds. J Natl Cancer Inst. 89:182–185.PubMedCrossRefGoogle Scholar
  14. Campbell MJ, Park S, Uskokovic MR, Dawson MI, Koeffler HP. 1998. Expression of retinoic acid receptor-beta sensitizes prostate cancer cells to growth inhibition mediated by combinations of retinoids and a 19-nor hexafluoride vitamin D3 analogy. Endocrinology 139:1972–1980.PubMedCrossRefGoogle Scholar
  15. Campbell MJ, Reddy GS, Koeffler HP. 1997b. Vitamin D3 analogs and their 24-oxo metabolites equally inhibit clonal proliferation of a variety of cancer cells but have differing molecular effects. J Cell Biochem 66:413–425.PubMedCrossRefGoogle Scholar
  16. Carlberg C, Polly P. 1998. Gene regulation by vitamin D3. Crit Rev Eukaryot Gene Expr. 8:19–42.PubMedCrossRefGoogle Scholar
  17. Chen TC, Schwartz GG, Burnstein KL, Lokeshwar BL, Holick MF. 2000. The in vitro evaluation of 25-hydroxyvitamin D3 and 19-nor-1alpha,25-dihydroxyvitamin D2 as therapeutic agents for prostate cancer. Clin Cancer Res. 6:901–908.PubMedGoogle Scholar
  18. Cho YL, Christensen C, Saunders DE, Lawrence WD, Deppe G, Malviya VK, Malone JM. 1991. Combined effects of 1,25-dihydroxyvitamin D3 and platinum drugs on the growth of MCF-7 cells. Cancer Res. 51:2848–2853.PubMedGoogle Scholar
  19. Crescioli C, Maggie M, Vannelli GB, Luconi M, Salerno R, Barni T, Gulisano M, Forti G, Serio M. 2000. Effect of a vitamin D3 analogue on keratinocyte growth factor-induced cell proliferation in benign prostate hyperplasia. J Clin Endocrinol Metab. 85:2576–2583.PubMedCrossRefGoogle Scholar
  20. Danielpour D. 1996. Induction of transforming growth factor-beta autocrine activity by all-trans-retinoic acid and 1 alpha,25-dihydroxyvitamin D3 in NRP-152 rat prostatic epithelial cells. J Cell Physiol 166:231–239.PubMedCrossRefGoogle Scholar
  21. Datto MB, Li Y, Panus JF, Howe DJ, Xiong Y, Wang XF. 1995. Transforming growth factor beta induces the cyclin-dependent kinase inhibitor p21 through a p53-independent mechanism. Proc Natl Acad Sci USA 92:5545–5549PubMedCrossRefGoogle Scholar
  22. Djavan B, Waldert M, Seitz C, Marberger M. 2001. Insulin-like growth factors and prostate cancer. World J Urol. 19:225–233.PubMedCrossRefGoogle Scholar
  23. Dusso A, Brown A, Slatopolsky E. 1994. Extrarenal production of calcitriol. Semin Nephrol 14:144–155.PubMedGoogle Scholar
  24. Falkenstein E, Tillmann H-C, Christ M., Fuering M. 2000. Multiple actions of steroid hormones-a focus on rapid, nongenomic effects. Pharmacological Reviews 52:513–555.PubMedGoogle Scholar
  25. Gardezi SA, Nguyen C, Malloy PJ, Posner GH, Feldman D, Peleg S. 2001. A rationale for treatment of hereditary vitamin D-resistant rickets with analogs of 1 alpha,25-dihydroxyvitamin D(3). J Biol Chem. 276: 29148–29156.PubMedCrossRefGoogle Scholar
  26. Getzenberg RH, Light BW, Lapco PE, Konety BR, Nangia AK, Acierno JS, Dhir R, Shurin Z, Day RS, Trump DL, Johnson CS. 1997. Vitamin D inhibition of prostate adenocarcinoma growth and metastasis in the Dunning rat prostate model system. Urology. 50:999–1006.PubMedCrossRefGoogle Scholar
  27. Gregory CW, He B, Johnson RT, Ford OH, Mohler JL, French FS, Wilson EM. 2001. A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Res. 61:4315–4319.PubMedGoogle Scholar
  28. Grimberg A, Cohen P. 2000. Role of insulin-like growth factors and their binding proteins in growth control and carcinogenesis. J Cell Physiol. 183:1–9.PubMedCrossRefGoogle Scholar
  29. Gross C, Skowronski RJ, Plymate SR, Rhim JS, Peehl DM, Feldman D. 1996. Simian virus 40-, but not human papillomavirus-, transformation of prostatic cells results in loss of growth-inhibition by 1,25-dihydroxyvitamin D3 Int J Oncology 8:41–47.Google Scholar
  30. Gross C, Stamey T, Hancock S, Feldman D. 1998. Treatment of early recurrent prostate cancer with 1,25-dihydroxyvitamin D3 (calcitriol). J Urol. 159:2035–2039; discussion 2039–2040.PubMedCrossRefGoogle Scholar
  31. Gudas JM, Nguyen H, Li T, Cowan KH. 1995. Hormone-dependent regulation of BRCA1 in human breast cancer cells. Cancer Res. 55:4561–4565.PubMedGoogle Scholar
  32. Guo Y, Kyprianou N. 1998. Overexpression of transforming growth factor TGF-beta1 type II receptor restores TGF-beta1 sensitivity and signaling in human prostate cancer cells. Cell Growth Differ. 9:185–193.PubMedGoogle Scholar
  33. Guyton KZ, Kensler TW, Posner GH. 2001. Cancer chemoprevention using natural vitamin D and synthetic analogs. Annu Rev Pharmacol Toxicol. 41:421–442.PubMedCrossRefGoogle Scholar
  34. Hansen CM, Binderup L, Hamberg KJ, Carlberg C. 2001. Vitamin D and cancer: effects of l,25(OH)2D3 and its analogs on growth control and tumorigenesis. Front Biosci. 6:D820–848.PubMedCrossRefGoogle Scholar
  35. Hedlund TE, Moffatt KA, Miller GJ, 1996a. Stable expression of the nuclear vitamin D receptor in the human prostatic carcinoma cell line JCA-1: evidence that the antiproliferative effects of 1 alpha, 25-dihydroxyvitamin D3 are mediated exclusively through the genomic signaling pathway. Endocrinology. 137:1554–1561.PubMedCrossRefGoogle Scholar
  36. Hedlund TE, Moffatt KA, Miller GJ. 1996b. Vitamin D receptor expression is required for growth modulation by 1 alpha,25-dihydroxyvitamin D3 in the human prostatic carcinoma cell line ALVA-31. J Steroid Biochem Mol Biol. 58:277–288.PubMedCrossRefGoogle Scholar
  37. Hershberger PA, Yu WD, Modzelewski RA, Rueger RM, Johnson CS, Trump DL. 2001. Calcitriol (1,25-dihydroxycholecalciferol) enhances paclitaxel antitumor activity in vitro and in vivo and accelerates paclitaxel-induced apoptosis. Clin Cancer Res 7:1043–1051.PubMedGoogle Scholar
  38. Hsu JY, Feldman D, McNeal JE, Peehl DM. 2001. Reduced lalpha-hydroxylase activity in human prostate cancer cells correlates with decreased susceptibility to 25-hydroxyvitamin D3-induced growth inhibition. Cancer Res. 61:2852–2856.PubMedGoogle Scholar
  39. Ikonen T, Matikainen M, Mononen N, Hyytinen ER, Helin HJ, Tommola S, Tammela TL, Pukkala E, Schleutker J, Kallioniemi OP, Koivisto PA. 2001. Association of e-cadherin germ-line alterations with prostate cancer. Clin Cancer Res. 7:3465–3471.PubMedGoogle Scholar
  40. Jensen SS, Madsen MW, Lukas J, Binderup L, Bartek J. 2001. Inhibitory effects of 1alpha,25-dihydroxyvitamin D(3) on the G(1)-S phase-controlling machinery. Mol Endocrinol. 15:1370–1380.PubMedCrossRefGoogle Scholar
  41. Jurutka PW, Whitfield GK, Hsieh JC, Thompson PD, Haussler CA, Haussler MR. 2001. Molecular nature of the vitamin D receptor and its role in regulation of gene expression. Rev Endocr Metab Disord. 2:203–16.PubMedCrossRefGoogle Scholar
  42. Kim HJ, Abdelkader N, Katz M, McLane JA. 1992. 1,25-Dihydroxy-vitamin-D3 enhances antiproliferative effect and transcription of TGF-beta1 on human keratinocytes in culture. J Cell Physiol. 151:579–587.PubMedCrossRefGoogle Scholar
  43. Kivineva M, Blauer M, Syvala H, Tammela T, Tuohimaa P. 1998. Localization of 1,25-dihydroxyvitamin D3 receptor (VDR) expression in human prostate. J Steroid Biochem Mol Biol. 66:121–127.PubMedCrossRefGoogle Scholar
  44. Kokontis JM, Hay N, Liao S. 1998. Progression of LNCaP prostate tumor cells during androgen deprivation: hormone-independent growth, repression of proliferation by androgen, and role for p27Kip1 in androgen-induced cell cycle arrest. Mol Endocrinol. 12:941–953.PubMedCrossRefGoogle Scholar
  45. Kokontis J, Takakura K, Hay N, Liao S. 1994. Increased androgen receptor activity and altered c-myc expression in prostate cancer cells after long-term androgen deprivation. Cancer Res. 54.1566–1573.PubMedGoogle Scholar
  46. Koli K, Keski-Oja J. 1995. 1,25-Dihydroxyvitamin D3 enhances the expression of transforming growth factor beta 1 and its latent form binding protein in cultured breast carcinoma cells. Cancer Res. 55:1540–1546.PubMedGoogle Scholar
  47. Koli K, Keski-Oja J. 1993. Vitamin D3 and calcipotriol enhance the secretion of transforming growth factor-beta 1 and-beta 2 in cultured murine keratinocytes. Growth Factors 8:153–163.PubMedCrossRefGoogle Scholar
  48. Konety BR, Schwartz GG, Acierno JS Jr, Becich MJ, Getzenberg RH. 1996. The role of vitamin D in normal prostate growth and differentiation. Cell Growth Differ. 7:1563–1570.PubMedGoogle Scholar
  49. Krill D, DeFlavia P, Dhir R, Luo J, Becich MJ, Lehman E, Getzenberg RH. 2001. Expression patterns of vitamin D receptor in human prostate. J Cell Biochem. 82:566–572PubMedCrossRefGoogle Scholar
  50. Lokeshwar BL, Schwartz GG, Selzer MG, Burnstein KL, Zhuang SH, Block NL, Binderup L. 1999. Inhibition of prostate cancer metastasis in vivo: a comparison of 1,23-dihydroxyvitamin D (calcitriol) and EB1089. Cancer Epidemiol Biomarkers Prev. 8:241–248.PubMedGoogle Scholar
  51. Ly LH, Zhao XY, Holloway L, Feldman D. 1999. Liarozole acts synergistically with 1alpha,25-dihydroxyvitamin D3 to inhibit growth of DU 145 human prostate cancer cells by blocking 24-hydroxylase activity. Endocrinology. 140:2071–2076.PubMedCrossRefGoogle Scholar
  52. Mangelsdorf DJ, Evans RM. 1995. The RXR heterodimers and orphan receptors. Cell. 83:841–850.PubMedCrossRefGoogle Scholar
  53. Martin JL, Pattison SL. 2000 Insulin-like growth factor binding protein-3 is regulated by dihydrotestosterone and stimulates deoxyribonucleic acid synthesis and cell proliferation in LNCaP prostate carcinoma cells. Endocrinology. 141:2401–2409.PubMedCrossRefGoogle Scholar
  54. Massague J, Blain SW, Lo RS. 2000. TGF-beta signaling in growth control, cancer, and heritable disorders. Cell. 103:295–309PubMedCrossRefGoogle Scholar
  55. McKenna NJ, Xu J, Nawaz Z, Tsai SY, Tsai MJ, O’Malley BW. 1999. Nuclear receptor coactivators: multiple enzymes, multiple complexes, multiple functions. J Steroid Biochem Mol Biol. 69:3–12.PubMedCrossRefGoogle Scholar
  56. Miller GJ, Stapleton GE, Ferrara JA, Lucia MS, Pfister S, Hedlund TE, Upadhya P. 1992. The human prostatic carcinoma cell line LNCaP expresses biologically active, specific receptors for 1 alpha,25-dihydroxyvitamin D3. Cancer Res. 52:515–520.PubMedGoogle Scholar
  57. Miller GJ, Stapleton GE, Hedlund TE, Moffat KA. 1995. Vitamin D receptor expression, 24-hydroxylase activity, and inhibition of growth by lalpha,25-dihydroxyvitamin D3 in seven human prostatic carcinoma cell lines. Clin Cancer Res 1:997–1003.PubMedGoogle Scholar
  58. Miller WL, Portale AA. 2001. Genetics of vitamin D biosynthesis and its disorders. Best Pract Res Clin Endocrinol Metab. 15:95–109.PubMedCrossRefGoogle Scholar
  59. Moffatt KA, Johannes WU, Hedlund TE, Miller GJ. 2001. Growth inhibitory effects of 1 alpha, 25-dihydroxyvitamin D(3) are mediated by increased levels of p21 in the prostatic carcinoma cell line ALVA-31. Cancer Res. 61:7122–7129.PubMedGoogle Scholar
  60. Moffatt KA, Johannes WU, Miller GJ. 1999. lAlpha,25dihydroxyvitamin D3 and platinum drugs act synergistically to inhibit the growth of prostate cancer cell lines. Clin Cancer Res. 5:695–703.PubMedGoogle Scholar
  61. Narvaez CJ, Welsh J. 1997. Differential effects of 1,25-dihydroxyvitamin D3 and tetradecanoylphorbol acetate on cell cycle and apoptosis of MCF-7 cells and a vitamin D3-resistant variant. Endocrinology. 138:4690–4698.PubMedCrossRefGoogle Scholar
  62. Osborn JL, Schwartz GG, Smith DC, Bahnson R, Day R, and Trump DL 1995. Phase II trial of oral 1,25-dihydroxyvitamin D (calcitriol) in hormone refractory prostate cancer. Urol Oncol 1: 195–198.PubMedCrossRefGoogle Scholar
  63. Palmer HG, Gonzalez-Sancho JM, Espada J, Berciano MT, Puig I, Baulida J, Quintanilla M, Cano A, de Herreros AG, Lafarga M, Munoz A. 2001. Vitamin D(3) promotes the differentiation of colon carcinoma cells by the induction of E-cadherin and the inhibition of beta-catenin signaling. J Cell Biol. 154:369–387.PubMedCrossRefGoogle Scholar
  64. Peehl DM, Seto E, Feldman D. 2001. Rationale for combination ketoconazole/ vitamin D treatment of prostate cancer. Urology. 58:123–126.PubMedCrossRefGoogle Scholar
  65. Peehl DM, Skowronski RJ, Leung GK, Wong ST, Stamey TA, Feldman D. 1994. Antiproliferative effects of 1,25-dihydroxyvitamin D3 on primary cultures of human prostatic cells. Cancer Res. 54:805–810.PubMedGoogle Scholar
  66. Platz EA, Hankinson SE, Hollis BW, Colditz GA, Hunter DJ, Speizer FE, Giovannucci E. 2000. Plasma 1,25-dihydroxy-and 25-hydroxyvitamin D and adenomatous polyps of the distal colorectum. Cancer Epidemiol Biomarkers Prev. 9:1059–1065.PubMedGoogle Scholar
  67. Pols HA, Birkenhager JC, Foekens JA, van Leeuwen JP. 1990. Vitamin D: a modulator of cell proliferation and differentiation. J Steroid Biochem Mol Biol. 37:873–876.PubMedCrossRefGoogle Scholar
  68. Rachez C, Freedman LP. 2000. Mechanisms of gene regulation by vitamin D(3) receptor: a network of coactivator interactions. Gene. 246:9–21.PubMedCrossRefGoogle Scholar
  69. Rashid SF, Moore JS, Walker E, Driver PM, Engel J, Edwards CE, Brown G, Uskokovic MR, Campbell MJ. 2001. Synergistic growth inhibition of prostate cancer cells by 1 alpha,25 Dihydroxyvitamin D(3) and its 19-nor-hexafluoride analogs in combination with either sodium butyrate or trichostatin A. Oncogene. 20:1860–1872.PubMedCrossRefGoogle Scholar
  70. Reichrath J. 2001. Will analogs of 1,25-dihydroxyvitamin D(3) (calcitriol) open a new era in cancer therapy? Onkologie. 24:128–133.PubMedCrossRefGoogle Scholar
  71. Sampson ER, Yeh SY, Chang HC, Tsai MY, Wang X, Ting HJ, Chang C. 2001. Identification and characterization of androgen receptor associated coregulators in prostate cancer cells. J Biol Regul Homeost Agents 15:123–129.PubMedGoogle Scholar
  72. Saunders DE, Christensen C, Wappler NL, Cho YL, Lawrence WD, Malone JM, Malviya VK, Deppe G. 1993. Additive inhibition of RL95-2 endometrial carcinoma cell growth by carboplatin and 1,25 dihydroxyvitamin D3. Gynecol Oncol. 51:155–159.PubMedCrossRefGoogle Scholar
  73. Schwartz GG, Hill CC, Oeler TA, Becich MJ, Bahnson RR. 1995. l,25-Dihydroxy-16-ene-23-yne-vitamin D3 and prostate cancer cell proliferation in vivo. Urology. 46:365–369.PubMedCrossRefGoogle Scholar
  74. Schwartz GG, Hulka BS. 1990. Is vitamin D deficiency a risk factor for prostate cancer? (Hypothesis). Anticancer Res. 10:1307–11.PubMedGoogle Scholar
  75. Schwartz GG, Oeler TA, Uskokovic MR, Bahnson RR. 1994. Human prostate cancer cells: inhibition of proliferation by vitamin D analogs. Anticancer Res. 14:1077–1081.PubMedGoogle Scholar
  76. Schwartz GG, Whitlatch LW, Chen TC, Lokeshwar BL, Holick MF. 1998. Human prostate cells synthesize 1,25-dihydroxyvitamin D3 from 25-hydroxyvitamin D3. Cancer Epidemiol Biomarkers Prev. 7:391–395.PubMedGoogle Scholar
  77. Shang Y, Hu X, DiRenzo J, Lazar MA, Brown M. 2000. Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription. Cell. 103:843–852.PubMedCrossRefGoogle Scholar
  78. Sheaff RJ, Singer JD, Swanger J, Smitherman M, Roberts JM, Clurman BE. 2000. Proteasomal turnover of p21Cipl does not require p21Cipl ubiquitination. Mol Cell 5:403–410.PubMedCrossRefGoogle Scholar
  79. Skowronski RJ, Peehl DM, Feldman D. 1993. Vitamin D and prostate cancer: 1,25 dihydroxyvitamin D3 receptors and actions in human prostate cancer cell lines. Endocrinology. 132:1952–1960.PubMedCrossRefGoogle Scholar
  80. Skowronski RJ, Peehl DM, Feldman D. 1995. Actions of vitamin D3, analogs on human prostate cancer cell lines: comparison with 1,25-dihydroxyvitamin D3. Endocrinology. 136:20–26.PubMedCrossRefGoogle Scholar
  81. Smith DC, Johnson CS, Freeman CC, Muindi J, Wilson JW, Trump DL. 1999. A Phase I trial of calcitriol (1,25-dihydroxycholecalciferol) in patients with advanced malignancy. Clin Cancer Res. 5:1339–1345.PubMedGoogle Scholar
  82. Umekita Y, Hiipakka RA, Kokontis JM, Liao S. 1996. Human prostate tumor growth in athymic mice: inhibition by androgens and stimulation by finasteride. Proc Natl Acad Sci USA. 93:11802–11807.PubMedCrossRefGoogle Scholar
  83. van den Bernd GJ, Pols HA, van Leeuwen JP. 2000. Anti-tumor effects of 1,25-dihydroxyvitamin D3 and vitamin D analogs. Curr Pharm Des. 2000 6:717–732.Google Scholar
  84. Vaughn JP, Cirisano FD, Huper G. Berchuck A, Futreal PA, Marks JR, Iglehart JD. 1996. Cell cycle control of BRCA2. Cancer Res. 56:4590–4594.PubMedGoogle Scholar
  85. Verlinden L, Verstuyf A, Convents R, Marcelis S, Van Camp M, Bouillon R. 1998. Action of l,25(OH)2D3 on the cell cycle genes, cyclin Dl, p21 and p27 in MCF-7 cells. Mol Cell Endocrinol. 142:57–65.PubMedCrossRefGoogle Scholar
  86. Walters MR. 1992. Newly identified actions of the vitamin D endocrine system. Endocr Rev. 13:719–764.PubMedGoogle Scholar
  87. Wang QM, Jones JB, Studzinski GP. 1996. Cyclin-dependent kinase inhibitor p27 as a mediator of the Gl-S phase block induced by 1,25-dihydroxyvitamin D3 in HL60 cells. Cancer Res. 56:264–267.PubMedGoogle Scholar
  88. Wilding G, Zugmeier G, Knabbe C, Flanders K, Gelmann E. 1989. Differential effects of transforming growth factor beta on human prostate cancer cells in vitro. Mol Cell Endocrinol. 62:79–87.PubMedCrossRefGoogle Scholar
  89. Wu G, Fan RS, Li W, Ko TC, Brattain MG. 1997. Modulation of cell cycle control by vitamin D3 and its analogue, EB1089, in human breast cancer cells. Oncogene 15:1555–1563.PubMedCrossRefGoogle Scholar
  90. Wu G, Fan RS, Li W, Srinivas V, Brattain MG. 1998. Regulation of transforming growth factor-beta type II receptor expression in human breast cancer MCF-7 cells by vitamin D3 and its analogues. J Biol Chem 273:7749–7756.PubMedCrossRefGoogle Scholar
  91. Yang ES, Maiorino CA, Roos BA, Knight SR, Burnstein, KL Vitamin D-mediated growth inhibition of an androgen-ablated LNCaP cell line model of human prostate cancer. Mol Cell Endocrinol (in press)Google Scholar
  92. Yang L, Yang J, Venkateswarlu S, Ko T, Brattain MG. 2001. Autocrine TGF-beta signaling mediates vitamin D3 analog-induced growth inhibition in breast cells. J Cell Physiol. 188:383–93.PubMedCrossRefGoogle Scholar
  93. Zhao XY, Ly LH, Peehl DM, Feldman D. 1997. 1alpha,25-dihydroxyvitamin D3 actions in LNCaP human prostate cancer cells are androgen-dependent. Endocrinology. 138:3290–3298.PubMedCrossRefGoogle Scholar
  94. Zhuang SH, Burnstein KL. 1998. Antiproliferative effect of lalpha,25-dihydroxyvitamin D3 in human prostate cancer cell line LNCaP involves reduction of cyclin-dependent kinase 2 activity and persistent Gl accumulation. Endocrinology. 139:1197–207.PubMedCrossRefGoogle Scholar
  95. Zhuang SH, Schwartz GG, Cameron D, Burnstein KL. 1997. Vitamin D receptor content and transcriptional activity do not fully predict antiproliferative effects of vitamin D in human prostate cancer cell lines. Mol Cell Endocrinol. 126:83–90.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Sceince+Business Media New York 2002

Authors and Affiliations

  • Kerry L. Burnstein
    • 1
  1. 1.University of Miami School of MedicineMiamiUSA

Personalised recommendations